Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab and Tadalafil in HNSCC
NCT03238365Phase 1Completed
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- Aug 2017
- Primary completion
- Jul 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of tadalafil in head and neck squamous cell carcinoma (HNSCC), sponsored by Sidney Kimmel Comprehensive Cancer Center. Started Aug 2017; status: completed.
02
Drugs
tadalafil
03
Conditions
head and neck squamous cell carcinoma (HNSCC)
Beyond the preview
Go deeper on NCT03238365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03238365.